Top Page
Nanobiotix
(NASDAQ:NBTX)
Nanobiotix (NBTX) vs. SPDR S&P 500 ETF (SPY)
Nanobiotix Business Overview & Revenue Model
Nanobiotix Earnings Call Summary
Nanobiotix Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.74M | -11.61M | 36.21M | 4.78M | 2.65M | 50.00K |
| Gross Profit | 5.74M | -11.61M | 36.21M | 3.79M | 2.65M | 50.00K |
| EBITDA | -33.99M | -58.32M | -23.69M | -44.22M | -45.60M | -31.49M |
| Net Income | -51.64M | -68.13M | -39.70M | -57.04M | -47.00M | -33.62M |
Balance Sheet | ||||||
| Total Assets | 45.17M | 67.42M | 93.90M | 59.77M | 101.77M | 134.03M |
| Cash, Cash Equivalents and Short-Term Investments | 28.82M | 49.74M | 75.28M | 41.39M | 83.92M | 119.15M |
| Total Debt | 51.24M | 50.90M | 50.56M | 53.17M | 46.02M | 48.98M |
| Total Liabilities | 114.13M | 133.12M | 95.74M | 86.81M | 74.98M | 63.56M |
| Stockholders Equity | -68.95M | -65.70M | -1.84M | -27.05M | 26.79M | 70.47M |
Cash Flow | ||||||
| Free Cash Flow | -31.64M | -20.40M | -12.81M | -37.20M | -30.11M | -27.64M |
| Operating Cash Flow | -31.13M | -19.55M | -12.48M | -37.10M | -29.87M | -27.54M |
| Investing Cash Flow | -617.00K | -955.00K | -349.00K | 138.00K | -242.00K | -112.00K |
| Financing Cash Flow | -5.31M | -5.13M | 46.77M | -5.65M | -5.18M | 111.77M |
Nanobiotix Technical Analysis
Nanobiotix Risk Analysis
Nanobiotix Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $2.27B | -9.45 | -68.33% | ― | ― | -38.04% | |
61 Neutral | $1.32B | -18.69 | -22.38% | ― | 2147.20% | -269.99% | |
52 Neutral | $1.64B | -12.79 | -40.80% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.00B | -7.87 | -26.64% | ― | ― | -103.95% | |
48 Neutral | $1.12B | -29.12 | ― | ― | ― | ― | |
40 Neutral | $1.31B | -7.11 | -85.59% | ― | ― | 0.69% |
Nanobiotix Corporate Events
On December 1, 2025, Nanobiotix S.A. announced the disclosure of transactions by persons discharging managerial responsibilities in compliance with EU Market Abuse Regulation. This announcement included details of a significant transaction on November 26, 2025, where shares were sold to repay bank loans used for financing stock options. This transaction allowed the company to eliminate the pledge on the remaining shares, potentially improving its financial flexibility and stakeholder confidence.
On November 24, 2025, Nanobiotix announced significant progress in its operations and financial strategy, including the closing of a non-dilutive royalty financing deal with HealthCare Royalty valued at up to $71 million. This move is expected to support the company’s long-term growth. Additionally, the company reported advancements in its JNJ-1900 (NBTXR3) clinical development program, including the transfer of the NANORAY-312 study sponsorship to Johnson & Johnson and the presentation of new data from a Phase 1 esophageal cancer study. The company also highlighted progress in its Curadigm Nanoprimer program, with new patent applications and collaborations. These developments position Nanobiotix for accelerated growth in 2026, with ongoing and upcoming clinical trials expected to provide further insights into the potential of its innovative cancer treatments.
On November 13, 2025, Nanobiotix announced significant advancements in its Curadigm Nanoprimer platform, including the filing of four new patent applications to expand its intellectual property portfolio. The company presented new preclinical data at the 2025 Partnership Opportunities in Drug Delivery conference, showcasing the Nanoprimer’s potential to improve the delivery of therapeutic vaccines. These developments are expected to drive long-term growth for Nanobiotix by supporting both internal pipeline development and external collaborations, with numerous material transfer agreements already in place.
On November 14, 2025, Nanobiotix announced its updated voting rights and share capital information as of October 31, 2025. The company reported 48,237,471 shares outstanding, with 50,267,962 theoretical voting rights and 50,245,844 exercisable voting rights. This announcement is significant for stakeholders as it provides transparency in shareholder voting power and aligns with regulatory requirements.
On November 11, 2025, Nanobiotix announced its participation in the Jefferies London Healthcare Conference, scheduled for November 17, 2025. The company’s CEO, Laurent Levy, and CFO, Bart van Rhijn, will engage in a fireside chat at the event, which will be webcast live. This participation underscores Nanobiotix’s commitment to engaging with the investor community and highlights its strategic positioning in the biotechnology industry.
On November 3, 2025, Nanobiotix announced its participation in several investor conferences scheduled for the week of November 10, 2025. The company’s management, including CEO Laurent Levy and CFO Bart van Rhijn, will present at the UBS Global Healthcare Conference, Guggenheim’s Annual Healthcare Innovation Conference, and the Stifel Healthcare Conference. These events are expected to enhance Nanobiotix’s visibility within the healthcare investment community and potentially attract new stakeholders.
On October 31, 2025, Nanobiotix announced a strategic royalty monetization agreement with HealthCare Royalty, securing up to $71 million in non-dilutive funding. This agreement is expected to extend the company’s cash runway into early 2028, supporting the development of its nanotherapeutic platforms and advancing key milestones in head and neck and lung cancer treatments. The deal involves HealthCare Royalty receiving a capped portion of milestones and royalties from sales of JNJ-1900 (NBTXR3), a novel oncology product. This financing aims to establish a financial foundation for Nanobiotix’s long-term growth and self-sustainability, reflecting confidence in its innovative cancer treatment approach.
On October 24, 2025, Nanobiotix announced updates to its JNJ-1900 (NBTXR3) clinical development program, highlighting the transfer of sponsorship and operational control of the Phase 3 NANORAY-312 trial to Johnson & Johnson. This strategic move is expected to enhance the development and potential scalability of NBTXR3 across various solid tumor indications, especially in combination with radiotherapy. The interim data for the NANORAY-312 trial is anticipated to be analyzed and reported in the first half of 2027, marking a significant milestone in the company’s collaboration with J&J and its ongoing efforts to expand treatment possibilities for cancer patients.
On October 15, 2025, Nanobiotix announced its voting rights and share capital details as of September 30, 2025. The company reported 48,237,471 outstanding shares, with 50,318,257 theoretical voting rights and 50,296,139 exercisable voting rights. This update is crucial for stakeholders to understand the company’s current shareholder structure and voting power distribution.
On October 1, 2025, Nanobiotix announced promising initial data from a Phase 1 study evaluating JNJ-1900 (NBTXR3) for esophageal cancer treatment. The study, presented at the ASTRO 2025 Annual Meeting, showed a high disease control rate of 85% and an objective response rate of 69% among 13 patients, with the treatment being well-tolerated. This development could potentially open new indications for JNJ-1900 (NBTXR3) and enhance Nanobiotix’s positioning in the oncology market, offering a novel approach that may reduce the need for invasive procedures like esophagectomy.
On September 30, 2025, Nanobiotix announced its half-year financial results and provided a business update. The company reported significant operational progress, including the expansion of its clinical development program for JNJ-1900 (NBTXR3) and regulatory harmonization efforts in Europe. Financially, Nanobiotix strengthened its position by amending its global licensing agreement with Johnson & Johnson, extending its cash visibility to mid-2026. Despite a net loss of €5.4 million for the first half of 2025, the company reduced its R&D expenses and maintained stable SG&A costs. However, concerns about its ability to continue as a going concern persist, with active discussions for non-dilutive financing underway to extend its cash runway beyond 2026.
On September 30, 2025, Nanobiotix S.A. released its half-year financial report for the period from January 1 to June 30, 2025. The report highlights significant events and activities, including the development and commercialization of its product JNJ-1900 through a license agreement with Janssen. The company is focused on expanding the pipeline for JNJ-1900 and completing clinical trials, which are crucial for its future prospects and market positioning.
On September 29, 2025, Nanobiotix announced updated Phase 1 results for their study on JNJ-1900 (NBTXR3) in combination with anti-PD-1 therapy for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC). The treatment demonstrated promising efficacy and safety, with high disease control and response rates in both anti-PD-1 naïve and resistant patients. The results suggest that JNJ-1900 (NBTXR3) could enhance local tumor control and potentially overcome resistance to immune checkpoint inhibitors, warranting further exploration in randomized controlled trials.
On September 17, 2025, Nanobiotix announced new results from a Phase 1 study evaluating JNJ-1900 (NBTXR3) in combination with immune checkpoint inhibitors for patients with primary cutaneous melanoma resistant to anti-PD-1. The study showed a favorable safety profile and early efficacy signals, with a 47.4% objective response rate and a 78.9% disease control rate. The findings suggest potential for further investigation in randomized clinical trials, potentially offering new treatment options for patients with advanced melanoma.
On September 12, 2025, Nanobiotix announced its updated voting rights and share capital information, reporting 48,236,771 shares outstanding as of August 31, 2025. The announcement, in compliance with French financial regulations, provides transparency to stakeholders and reinforces the company’s commitment to regulatory standards, potentially impacting its market positioning and investor relations.